Primary leiomyosarcoma of the seminal vesicle: Case report and review of the literature
© Cauvin et al; licensee BioMed Central Ltd. 2011
Received: 22 March 2011
Accepted: 29 July 2011
Published: 29 July 2011
Primary leiomyosarcoma of the seminal vesicle is exceedingly rare.
We report a case of a 59-year-old man with tumour detected by rectal symptoms and ultrasonography. Computed tomography and magnetic resonance imaging suggested an origin in the right seminal vesicle. Transperineal biopsy of the tumour revealed leiomyosarcoma. A radical vesiculo-prostactectomy with bilateral pelvic lymphadenectomy was performed. Pathological examination showed a grade 2 leiomyosarcoma of the seminal vesicle. The patient received adjuvant radiotherapy. He developed distant metastases 29 months after diagnosis, and received chemotherapy. Metastatic disease was controlled by second-line gemcitabine-docetaxel combination. Fifty-one months after diagnosis of the primary tumour, and 22 months after the first metastases, the patient is alive with excellent performance status, and multiple asymptomatic stable lung and liver lesions.
We report the eighth case of primary leiomyosarcoma of the seminal vesicle and the first one with a so long follow-up.
Keywordsleiomyosarcoma seminal vesicle
Less than 5% of soft tissue sarcomas (STS) arise from the genitourinary tract. Leiomyosarcomas of the seminal vesicle are exceedingly rare. To our knowledge, only seven cases have been reported to date in the English literature and all with a short follow-up [1–6]. Diagnosis, initially described as difficult because of invaded surrounding structures, which obscure the actual place of origin, is being facilitated by modern imaging techniques such as computed tomography and magnetic resonance imaging. Data on optimal treatment are limited, but radical surgery seems essential. The role of adjuvant chemotherapy and radiotherapy remains unclear. Here, we report an additional case of primary leiomyosarcoma of the seminal vesicle with a long follow-up of more than 4 years, and review the literature.
The patient was a 59-year old man, Caucasian type, without any specific medical personal or familial history. In October 2006, he underwent a pelvic ultrasonography (US) because he presented a "pressure sensation" in the rectum and rectal imperiosity for four weeks. Physical examination revealed no additional symptom, except the rectal examination that detected a 4-cm hard pre-rectal mass filling the right side of the pelvis. The WHO performance status was equal to 0. Ultrasonography (US) discovered a tumour located at the right side of the pelvis. Serum prostate-specific antigen levels were normal. The patient was thus referred to hospital.
Primary malignant tumours of the seminal vesicles are very rare. Among them, carcinomas are much more frequent than sarcomas . Primary leiomyosarcoma of the seminal vesicle is extremely rare with to our knowledge only seven cases reported in the English literature. Our case represents the eighth patient, and the first one with a follow-up superior to 30 months.
Eight cases of leiomyosarcoma of the seminal vesicle reported in literature
Pathological tumor size
14 months: no relapse, alive
24 months: no relapse, alive
29 months: metastasis (lung), alive with disease (doxorubicin)
rectal and pain
13 months: no relapse, alive
24 months: metastasis (kidney), alive with disease (CT)
urinary and pain
6 months: no relapse, alive
urinary and rectal
CT (MAID) and RT
20 months: no relapse, alive
29 months: metastases (sub-cutaneous, lung, liver: MAI); 51 months: alive with disease (gemcitabine-docetaxel)
Radiological imaging is useful for the diagnosis and staging of seminal vesicle tumours, notably to locate the initial site of tumour development. Indeed, these tumours tend to invade neighbouring structures in the retrovesical space, causing difficulty in determining the organ of origin, and leading to radical resection of several major organs. Generally the first exam is US either transrectal or transabdominal. More frequently, pelvic CT and above all MRI allow the localisation of the tumour in the seminal vesicle and a better appreciation of the locoregional extension before surgery. In our case, and as previously reported , MRI findings strongly suggested a tumour origin in the right seminal vesicle, followed by extension to adjacent organs (prostate, internal obturator muscle).
Sarcoma diagnosis is provided by pathological analysis of the tumour sample, either after needle biopsy (5 cases including ours), or after surgical resection (1 case). In all cases, definitive diagnosis was done by histological examination of the resected tumour. In our case, the finding of a small adenocarcinoma raised the possibility of a sarcomatoid carcinoma but the macroscopical presentation of a clearly extraprostatic tumour, the absence of any connection between the two proliferations, and negativity of epithelial markers by immunochemistry did not favour this diagnosis. Differential diagnosis also concerns leimoyosarcoma arising from adjacent organs (prostate, bladder, rectum) and secondarily invading the seminal vesicle. But today, thanks to the advent of modern imaging tools, the organ of origin can be documented in most of cases by looking at the epicentre of the mass and the pattern of displacement of adjacent organs .
The prognosis of leiomyosarcoma of the seminal vesicle is poor, and more unfavourable than other urological sarcoma arising from the bladder or paratesticular site . This is partly due to the uncommon form of presentation, delay in diagnosis, and difficulty in complete surgical excision. This overall poor prognosis is demonstrated in Table 1. Indeed, the median follow-up of the 8 cases is short (22 months; range, 6 to 51), and of note, the 3 patients with a follow-up superior to 24 months all experienced metastatic relapse at 24, 29, and 29 months. The 5 other patients, alive without any relapse, present a median follow-up of only 14 months (range, 6 to 24). Our case represents the one with the longest follow-up (51 months). Obviously, the small number of cases precludes any prognostic analysis. Metastatic relapses occurred in the 3 patients with microscopically incomplete resection (2 cases) and/or high grade (2 cases) and/or tumour size superior to 5 cm (2 cases), suggesting that those sarcomas share prognostic features with STS arising from other sites.
Data on optimal treatment are obviously limited. The main treatment is surgery, which consisted of a cystoprostatectomy with a pelvic lymphadenectomy in all reported cases, except ours where vesiculo-prostatectomy was done without cystectomy and without any local relapse during the follow-up. As usually in STS, only complete resection of the tumour offers a chance for a cure. In the literature, the margins were positive in only 2 cases. In our case the margins were very close, less than 1 mm, justifying the use of adjuvant radiation therapy. The role of adjuvant radiation therapy in visceral STS is not established , and only two out of 8 reported cases, including ours with very close margins, received such treatment. Of note, none of the 8 patients, including ours treated without cystectomy, experienced any local relapse during the available follow-up. Regarding adjuvant chemotherapy, its role in STS remains unclear , and only one patient received adjuvant combination of doxorubicin, ifosfamide and dacarbazine (MAID). Anthracycline-based chemotherapy was offered to the 3 patients at the time of metastatic relapse, but the response is documented in our case only. Our patient's disease progressed after 6 doxorubicin-ifosfamide cycles, but responded to second-line chemotherapy based on gemcitabine and docetaxel, as observed with leiomyosarcomas arising from other sites .
We report the eighth case of primary leiomyosarcoma of the seminal vesicle with the longest follow-up. As these tumours are exceptional and information about standard treatment is lacking, we think that case reports such as this one may serve as the only reference for clinicians taking care of these patients. Radical surgical excision is the best chance for cure, but the need for cystectomy must be discussed. Furthermore, like leiomyosarcomas from other sites, a multimodality treatment deserves to be discussed and systemic therapy to be improved given the metastatic risk and overall poor prognosis. In this context, the gemcitabine-docetaxel combination is likely so efficient than in other locations.
Written informed consent was obtained from the patient (February 2011) for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
soft tissue sarcoma
World Health Organisation
magnetic resonance imaging
Fédération Nationale des Centres de Lutte Contre le Cancer.
Our work is supported by Institut Paoli-Calmettes and University of Mediterranea. We thank our patient who kindly gave his consent for this publication. We thank Rebecca Tagett for editing the revised version.
- Agrawal V, Kumar S, Sharma D, Singh UR, Gupta A: Primary leiomyosarcoma of the seminal vesicle. Int J Urol. 2004, 11: 253-255. 10.1111/j.1442-2042.2003.00773.x.PubMedView Article
- Amirkhan RH, Molberg KH, Wiley EL, Nurenberg P, Sagalowsky AI: Primary leiomyosarcoma of the seminal vesicle. Urology. 1994, 44: 132-135. 10.1016/S0090-4295(94)80026-X.PubMedView Article
- Muentener M, Hailemariam S, Dubs M, Hauri D, Sulser T: Primary leiomyosarcoma of the seminal vesicle. J Urol. 2000, 164: 2027-10.1016/S0022-5347(05)66949-2.PubMedView Article
- Russo P, Brady MS, Conlon K, Hajdu SI, Fair WR, Herr HW, Brennan MF: Adult urological sarcoma. J Urol. 1992, 147: 1032-1036. discussion 1036-1037PubMed
- Schned AR, Ledbetter JS, Selikowitz SM: Primary leiomyosarcoma of the seminal vesicle. Cancer. 1986, 57: 2202-2206. 10.1002/1097-0142(19860601)57:11<2202::AID-CNCR2820571121>3.0.CO;2-H.PubMedView Article
- Upreti L, Bhargava SK, Kumar A: Imaging of primary leiomyosarcoma of the seminal vesicle. Australas Radiol. 2003, 47: 70-72. 10.1046/j.1440-1673.2003.01108.x.PubMedView Article
- Thiel R, Effert P: Primary adenocarcinoma of the seminal vesicles. J Urol. 2002, 168: 1891-1896. 10.1016/S0022-5347(05)64260-7.PubMedView Article
- Swallow CJ, Catton CN: Local management of adult soft tissue sarcomas. Semin Oncol. 2007, 34: 256-269. 10.1053/j.seminoncol.2007.03.008.PubMedView Article
- Blay JY, Le Cesne A: Adjuvant chemotherapy in localized soft tissue sarcomas: still not proven. Oncologist. 2009, 14: 1013-1020. 10.1634/theoncologist.2009-0126.PubMedView Article
- Hensley ML, Maki R, Venkatraman E, Geller G, Lovegren M, Aghajanian C, Sabbatini P, Tong W, Barakat R, Spriggs DR: Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol. 2002, 20: 2824-2831. 10.1200/JCO.2002.11.050.PubMedView Article
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/11/323/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.